WHO WE ARE
EmphyCorp is a Private NJ Biotech focused on Providing Safer Rx Nasal Spray Drugs with no known side effects for the treatment of major Respiratory Diseases and COVID-19, including Pulmonary Fibrosis, Cystic Fibrosis, COPD, Flu, COVID-19, and COVID Long Haulers Treatments.
Three Successful Phase III N115 Nasal Spray Clinical Trials were completed for Pulmonary Fibrosis, COVID-19, and COVID-19 Long Haulers (Long COVID) Treatments.
A Phase III Clinical Trial for Flu will start soon.
In 2021, a new Hypoxemia Drug Patent (7th Patent) was granted, while three additional Drug Patents are Pending.
Our Drug Patents total 70+ worldwide, including China.
N115 Non-Steroidal Nasal Spray with no known side effects increases Nasal Nitric Oxide that is beneficial to many Patients that have Hypoxemia symptoms (Low Oxygen, Shortness of Breath, Coughing, Headaches), even though they are taking existing approved drugs for Pulmonary Fibrosis, Cystic Fibrosis, COPD, Asthma, Heart Medications (like Entresto®), and more.
